Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of #2, indicating an improving earnings outlook compared to its competitor Johnson & Johnson. The stock trades within a 52-week range of $23.62 to $29.21 and has a market capitalization of approximately $155.6 billion. This price target raise reflects growing confidence in Pfizer's future performance but is not a guarantee of stock price movement.
Pfizer shares are currently priced at USD 27.47 on Pluang, showing a slight gain of 0.22% as of Oct 07, 2026 02:12 WIB. The stock's market cap stands at $156.23 billion, with a dividend yield of 6.28%, indicating steady investor interest despite a majority of sell orders at 71%.
Moderna's stock has soared 545% year-to-date, driven by its mRNA technology and a promising oncology pipeline including a personalized cancer vaccine. The company now joins the NASDAQ 100, increasing its visibility and institutional interest. Despite...
Vaccine stocks surged after a Siberian plague scare, but health officials have since declared the risk low, causing Novavax shares to drop 2% after a prior 20% spike. Novavax's rally was driven by speculation of government vaccine purchases, but the ...
Moderna shares surged 8% to $204.60 as investors anticipate the full Phase 3 melanoma vaccine trial data to be presented at the European Society for Medical Oncology (ESMO) congress in Madrid. The vaccine, developed with Merck, showed promising resul...
